Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
1,445 stopped studies mapped to Lymphoid Neoplasm and descendants · 89% state a reason
Over the 1,445 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT05611853 | Study of BN301, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell… | Phase 1 / Phase 2 | terminated | Nov 10, 2022 | BioNova Pharmaceuticals (Shanghai) LTD. | Due to company decision | Sponsor / business decision |
| NCT05641324 | A Study of ANV419 Alone or in Combination With Approved Treatments in Patients With… | Phase 1 | terminated | Dec 7, 2022 | Anaveon AG | The study was ended due to a lack of recruitment | Enrollment / accrual |
| NCT04912427 | Isatuximab, Velcade, and Dexamethasone in Patients With Multiple Myeloma and Severe… | Phase 1 | terminated | Jun 3, 2021 | Washington University School of Medicine | Low accrual | Enrollment / accrual |
| NCT03684694 | Safety and Efficacy Study of Loncastuximab Tesirine + Ibrutinib in Diffuse Large B-Cell… | Phase 1 / Phase 2 | terminated | Sep 26, 2018 | ADC Therapeutics S.A. | Administrative decision | Other (stated, no rule matched) |
| NCT04466475 | Radioimmunotherapy (211At-OKT10-B10) and Chemotherapy (Melphalan) Before Stem Cell… | Phase 1 | withdrawn | Jul 10, 2020 | Fred Hutchinson Cancer Center | NIH terminated funding. Study was closed before any participants were enrolled. | Enrollment / accrual |
| NCT05107856 | PRT1419 as Monotherapy or in Combination With Azacitidine or Venetoclax in R/R Myeloid or… | Phase 1 | terminated | Nov 4, 2021 | Prelude Therapeutics | Company Decision | Sponsor / business decision |
| NCT03151811 | A Study of Melphalan Flufenamide (Melflufen)-Dex or Pomalidomide-dex for RRMM Patients…(OCEAN) | Phase 3 | terminated | May 12, 2017 | Oncopeptides AB | Sponsor assessed all endpoints and collected Overall Survival data for another two years following… | Other (stated, no rule matched) |
| NCT01769222 | Ipilimumab and Local Radiation for Selected Solid Tumors | Phase 1 | terminated | Jan 16, 2013 | Stanford University | Planned Future Study | Other (stated, no rule matched) |
| NCT04025216 | A Study of CART-TnMUC1 in Patients With TnMUC1-Positive Advanced Cancers | Phase 1 | terminated | Jul 18, 2019 | Kite, A Gilead Company | The sponsor finds the risk/benefit analysis unfavorable and has terminated the study. | Other (stated, no rule matched) |
| NCT04465760 | Xisomab 3G3 for the Prevention of Catheter-Associated Thrombosis in Patients With Cancer… | Phase 2 | terminated | Jul 10, 2020 | OHSU Knight Cancer Institute | Insufficient accrual rate | Enrollment / accrual |
| NCT03495713 | Lymphoma RadVax LYMPHOMA: A PHASE II TRIAL OF NIVOLUMAB + LOW DOSE RADIOTHERAPY FOR… | Phase 2 | terminated | Apr 12, 2018 | Abramson Cancer Center at Penn Medicine | Covid-19 | COVID-19 / pandemic |
| NCT03422679 | Study of CB-103 in Adult Patients With Advanced or Metastatic Solid Tumours and… | Phase 1 / Phase 2 | terminated | Feb 6, 2018 | Cellestia Biotech AG | business reason | Sponsor / business decision |
| NCT04505813 | Antigen-specific T Cell Therapy for Patients With Relapsed Refractory Multiple Myeloma | Phase 1 / Phase 2 | suspended | Aug 10, 2020 | NexImmune Inc. | Lack of accrual | Enrollment / accrual |
| NCT04220008 | Vorinostat and Combination Chemotherapy Before Donor Stem Cell Transplantation for the… | Phase 2 | withdrawn | Jan 7, 2020 | M.D. Anderson Cancer Center | No Participants Enrolled | Enrollment / accrual |
| NCT03138499 | A Study of Nivolumab Plus Brentuximab Vedotin Versus Brentuximab Vedotin Alone in…(CheckMate 812) | Phase 3 | terminated | May 3, 2017 | Bristol-Myers Squibb | Insufficient enrollment. | Enrollment / accrual |
| NCT03502577 | BCMA-Specific CAR T-Cells Combined With a Gamma Secretase Inhibitor (JSMD194) to Treat… | Phase 1 | terminated | Apr 18, 2018 | Fred Hutchinson Cancer Center | Closed per SRC Low Accrual Policy | Enrollment / accrual |
| NCT03657251 | MMRF CureCloud Research Initiative | — | terminated | Sep 5, 2018 | Multiple Myeloma Research Foundation | The MMRF has learned of the limitations of using a blood sample to collect genomic data, compared… | Other (stated, no rule matched) |
| NCT03864419 | Rituximab Hyaluronidase in Combination With Chemotherapy in Treating Aggressive B-cell… | Phase 1 | terminated | Mar 6, 2019 | Fred Hutchinson Cancer Center | Closed per SRC Low Accrual Policy | Enrollment / accrual |
| NCT04187872 | LITT and Pembrolizumab in Recurrent Brain Metastasis(TORCH) | Phase 1 | terminated | Dec 5, 2019 | University of Florida | Sponsor terminated | Other (stated, no rule matched) |
| NCT05980507 | An Open Label, Single-arm Clinical Study Evaluating the Safety and Efficacy of ICI201… | Phase 1 | withdrawn | Aug 8, 2023 | The First Affiliated Hospital of Soochow University | Molecular development strategy adjustment | Sponsor / business decision |
| NCT04549363 | Characterization of Corneal Epithelial Changes in Participants Treated With Belantamab… | Phase 3 | terminated | Sep 16, 2020 | GlaxoSmithKline | The study has been terminated for reasons pertaining to feasibility | Other (stated, no rule matched) |
| NCT05321940 | Safety Trial of STING-dependent Activators and Stimulated Dendritic Cells for Aggressive… | Phase 1 | withdrawn | Apr 11, 2022 | Juan C. Ramos, MD | Investigator decision | Investigator |
| NCT04828174 | Anti-TRBC1 CAR-T Cell Therapy in Patients With TRBC1 Positive T Cell Malignancies | Phase 1 | suspended | Apr 1, 2021 | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | The trial was suspended due to the inability to enroll qualified participants | Enrollment / accrual |
| NCT04864522 | Phase I/II Study of SLAMF7 FPBMC/CS-1 FPBMC in Relapsed/Refractory Multiple Myeloma(MM FPBMC) | Phase 1 / Phase 2 | withdrawn | Apr 29, 2021 | University of Virginia | Slow accrual due to a crowded field of effective drugs by the time the study opened | Enrollment / accrual |
| NCT04978779 | A Study to Evaluate VIP152 in Subjects With Relapsed/Refractory Chronic Lymphocytic… | Phase 1 | terminated | Jul 27, 2021 | Vincerx Pharma, Inc. | Slow enrollment | Enrollment / accrual |
| NCT05647512 | Study of LM-305 in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) and Other… | Phase 1 / Phase 2 | withdrawn | Dec 12, 2022 | LaNova Medicines Limited | According to sponsor strategy | Sponsor / business decision |
| NCT05321862 | Relevance Evaluation of [68Ga]Ga-PentixaFor for Initial Staging and Detection of Minimal…(PENTI-MIDAS) | Phase 2 | withdrawn | Apr 11, 2022 | Nantes University Hospital | MIDAS inclusions terminated before first inclusion in PENTI-MIDAS | Other (stated, no rule matched) |
| NCT05138458 | A Study of MT-101 in Subjects With CD5+ Relapsed/Refractory TCL(IMAGINE) | Phase 1 / Phase 2 | suspended | Dec 1, 2021 | Myeloid Therapeutics | Temporary operational pause; no safety concerns. | Safety / toxicity |
| NCT03572634 | Phase 1/2 Study of TP-0903 (an Inhibitor of AXL Kinase) in Patients With Previously… | Phase 1 / Phase 2 | terminated | Jun 28, 2018 | Sumitomo Pharma America, Inc. | Given the extensive time projected to conclude the study hypothesis, it is no longer feasible to… | Other (stated, no rule matched) |
| NCT05221385 | Gentulizumab in Patients With Advanced Solid Malignancies and Non-Hodgkin Lymphoma | Phase 1 | terminated | Feb 3, 2022 | Changchun GeneScience Pharmaceutical Co., Ltd. | Due to changes in the sponsor's research strategy | Sponsor / business decision |
| NCT02188368 | Pomalidomide for Lenalidomide for Relapsed or Refractory Multiple Myeloma Patients | Phase 2 | terminated | Jul 11, 2014 | Oncotherapeutics | Lack of enrollment | Enrollment / accrual |
| NCT02294357 | Weekly 70 mg/m2 Carfilzomib for Multiple Myeloma Patients Refractory to 27 mg/m2… | Phase 2 | terminated | Nov 19, 2014 | Oncotherapeutics | Early termination due to the difficulties to enroll subjects. | Enrollment / accrual |
| NCT04684979 | Transplantation of Hematopoietic Stem Cells From HLA-compatible Donors in Patients With… | Phase 2 | withdrawn | Dec 28, 2020 | Baptist Health South Florida | The landscape of treatment for patients targeted for enrollment has significantly changed since the… | Enrollment / accrual |
| NCT05222438 | Trial of Loncastuximab Tesirine in High Risk Diffuse Large B-cell Lymphoma Post Transplant | Phase 2 | withdrawn | Feb 3, 2022 | Barbara Ann Karmanos Cancer Institute | No accrual of participants in 18 months | Enrollment / accrual |
| NCT02763384 | BL-8040 and Nelarabine for Relapsed or Refractory T-Acute Lymphoblastic Leukemia/… | Phase 2 | terminated | May 5, 2016 | Washington University School of Medicine | Low accrual | Enrollment / accrual |
| NCT04621604 | Evaluation of the Relationship Between Anti-PD-1 Exposure and Tumour VOLUME in Patients…(REVOLUMHOD) | N/A | terminated | Nov 9, 2020 | Rennes University Hospital | lack of eligible patients | Other (stated, no rule matched) |
| NCT03733691 | Ph 2 Maintenance Trial: Ixazomib vs Ixazomib-Lenalidomide for MM Patients | Phase 2 | terminated | Nov 7, 2018 | Oncotherapeutics | Insufficient enrollment | Enrollment / accrual |
| NCT04843579 | Treatment of Selinexor in Combination With Clarithromycin, Pomalidomide and Dexamethasone…(ClaSPd) | Phase 2 | terminated | Apr 13, 2021 | Weill Medical College of Cornell University | low enrollment | Enrollment / accrual |
| NCT03679624 | Daratumumab Plus Ibrutinib in Patients With Waldenstrӧm's Macroglobulinemia | Phase 2 | terminated | Sep 20, 2018 | Weill Medical College of Cornell University | Low accrual | Enrollment / accrual |
| NCT04699461 | Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine Versus Idelalisib in…(LOTIS-6) | Phase 2 | terminated | Jan 7, 2021 | ADC Therapeutics S.A. | Administrative decision (not due to safety reason) | Safety / toxicity |
| NCT03318861 | Study to Evaluate the Safety and Efficacy of KITE-585 in Participants With… | Phase 1 | terminated | Oct 24, 2017 | Kite, A Gilead Company | The study was terminated due to lack of efficacy | Efficacy / futility |
| NCT04805203 | Analysis of the Immune Parameters of COVID-19 Infection in Patients With Multiple Myeloma(Covimmunomm) | N/A | terminated | Mar 18, 2021 | Intergroupe Francophone du Myelome | Recruitment delay due to difficulties to involve patient at Covid diagnosis in hematology… | COVID-19 / pandemic |
| NCT05867030 | Parsaclisib in Patients With Relapsed or Refractory Follicular Lymphoma | Phase 1 | withdrawn | May 19, 2023 | Innovent Biologics (Suzhou) Co. Ltd. | Development strategy adjustment | Sponsor / business decision |
| NCT03947255 | A Study of Retreatment With Brentuximab Vedotin in Subjects With Classic Hodgkin Lymphoma… | Phase 2 | terminated | May 13, 2019 | Seagen Inc. | Study stopped early due to low patient accrual. | Enrollment / accrual |
| NCT04840784 | First-in Human (FIH) Trial of ETH-155008 in Subjects With B-NHL, CLL/SLL and AML | Phase 1 | terminated | Apr 12, 2021 | Shengke Pharmaceuticals Pty Ltd | The reasons for early termination is due to slow recruitment | Enrollment / accrual |
| NCT02957019 | A Phase I/II Study of the Tumor-targeting Human L19-IL2 Monoclonal Antibody-cytokine… | Phase 1 / Phase 2 | terminated | Nov 7, 2016 | Philogen S.p.A. | Slow progression due to difficulties in finding eligible patients. Competitive clinical trials with… | Other (stated, no rule matched) |
| NCT04795869 | Brentuximab Vedotin and Pembrolizumab in Treating Patients With Recurrent Peripheral… | Phase 2 | withdrawn | Mar 12, 2021 | Northwestern University | Study inactivated due to zero accruals | Enrollment / accrual |
| NCT05961696 | A Phase I Study of Mosunetuzumab for Relapsed or Refractory B-Cell Acute Lymphoblastic… | Phase 1 | withdrawn | Jul 27, 2023 | M.D. Anderson Cancer Center | 0 accrual | Enrollment / accrual |
| NCT01177683 | Bendamustine in Combination With Bortezomib and Pegylated Liposomal Doxorubicin for… | Phase 1 / Phase 2 | terminated | Aug 9, 2010 | Sherif Farag, MB, BS | Lack of accrual | Enrollment / accrual |
| NCT02065869 | Safety Study of Gene Modified Donor T-cells Following TCRαβ+ Depleted Stem Cell Transplant | Phase 1 / Phase 2 | terminated | Feb 19, 2014 | Bellicum Pharmaceuticals | Sponsor decision | Sponsor / business decision |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 24 days agoSource updated Feb 21, 2024source: clinicaltrials